Publications by authors named "Mir Mohammad Ibna Masud"
Article Synopsis
- Bangladesh faces ongoing cholera epidemics, resulting in over 300,000 severe cases and 4,500 deaths annually, with inadequate oral cholera vaccines limiting control efforts.
- A public-private partnership led to the development and testing of a locally-produced Oral Cholera Vaccine (OCV) called Cholvax, compared to the internationally licensed Shanchol.
- A clinical trial involving 2,052 healthy participants showed that Cholvax was safe and had comparable immunogenicity to Shanchol, supporting its potential use to help reduce cholera in Bangladesh.
Worldwide Hepatitis B is known as one of the imperative causes of mortality and morbidity as well as occupational health hazard among health workers. Bangladesh is intermediate endemic country for Hepatitis B infection for which the government has introduced hepatitis B vaccination into the Expanded Programme on Immunization (EPI) nationwide since 2009 for new born children. However, the people who were born before 2009, was dependent on imported hepatitis B vaccine as there was no locally manufactured hepatitis B vaccine in Bangladesh.
View Article and Find Full Text PDF